Tag: molnupiravir

Treating COVID-19 infection with molnupiravir does not decrease deaths or hospital admission in high-risk, vaccinated patients, but can lead to quicker recovery

Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated…

SARS-CoV-2 variants of concern and the biological sex of patients affect the efficacy of molnupiravir, the first orally available drug…

A new analysis of data on the ‘COVID-19 pill’ molnupiravir shows it appears to clear active SARS-CoV-2 virus equally well…

Press release: Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that…